Azacitidine and lenalidomide as an alternative treatment for refractory acute myeloid leukemia: a case report.
| Autor: | Todaro J; Faculdade de Medicina do ABC (FMABC), Santo André, Brazil., Bollmann PW; Faculdade de Medicina do ABC (FMABC), Santo André, Brazil., Rother ET; Institute of Education and Research, Hospital Israelita Albert Einstein (HIAE), São Paulo, Brazil., del Giglio A; Faculdade de Medicina do ABC (FMABC), Santo André, Brazil. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Sao Paulo medical journal = Revista paulista de medicina [Sao Paulo Med J] 2015 May-Jun; Vol. 133 (3), pp. 271-4. Date of Electronic Publication: 2014 Sep 19. |
| DOI: | 10.1590/1516-3180.2012.6790006 |
| Abstrakt: | Context: Refractory acute myeloid leukemia (AML) is a difficult disease to control with second or third-line chemotherapy regimens. In this report, we describe using azacitidine in combination with lenalidomide as salvage therapy. Case Report: 52-year-old female was diagnosed with refractory AML and high-risk cytogenetics: complex monosomal karyotype consisting of t (3, 3) in association with monosomy 7 and del 5q. Morphological remission associated with maintenance of the cytogenetic abnormality of chromosome 3 and disappearance of the abnormalities relating to chromosomes 5 and 7 was achieved after three cycles of combination therapy with azacitidine and lenalidomide. Conclusion: Azacitidine plus lenalidomide can be a therapeutic option for patients with refractory AML, as illustrated in this case. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|